Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from GeoVax Labs ( (GOVX) ).
On December 19, 2025, GeoVax Labs, Inc. entered into agreements with Roth Capital Partners and a group of institutional and individual investors for a public offering of approximately 13.2 million common units, each consisting of one share of common stock and warrants to purchase additional shares, at a price of $0.245 per unit, with warrants exercisable immediately at the same price for five years. The transaction, which closed on December 22, 2025, is expected to generate about $3.2 million in gross proceeds and approximately $2.9 million in net proceeds, which GeoVax plans to use for working capital and general corporate purposes; the company also agreed to short-term restrictions on issuing additional equity and variable-rate securities, a move that shores up near-term liquidity while temporarily limiting further dilution and complex financings for existing shareholders.
The most recent analyst rating on (GOVX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and immunotherapies for solid tumor cancers. Its lead programs include GEO-CM04S1, a next-generation COVID-19 vaccine in multiple Phase 2 trials targeting immunocompromised and healthy patients as both primary and booster vaccinations, and Gedeptin, an oncolytic gene-directed therapy recently evaluated in a multicenter Phase 1/2 trial for advanced head and neck cancers. The company is also advancing a vaccine targeting Mpox and smallpox, with plans to move directly into Phase 3 clinical evaluation based on recent European regulatory guidance, supported by a broad intellectual property portfolio and worldwide rights to its technologies and product candidates.
Average Trading Volume: 1,394,046
Technical Sentiment Signal: Sell
Current Market Cap: $4.79M
Find detailed analytics on GOVX stock on TipRanks’ Stock Analysis page.